Osteoarthritis News

As concern about the cost of health care continues to be a top concern for most Americans, those who look at the potential cost of dealing with the osteoarthritis symptoms in a hip or knee may believe their money is better spent by just "getting it fixed" with joint replacement.

Nine supplements for osteoarthritis that ConsumerLab.com recently selected for testing were found to be contaminated with lead, lack all or some of a key ingredient or have other quality problems.

Dr. Gerald King, an orthopedic surgeon at Western Carolina Orthopaedic Specialists, will address arthritis and its effects on the knees and hips during a "Conquering Arthritis" Lunch and Learn session July 13 at Haywood Regional Health & Fitness Center.

By: Jason Napodano, CFA 0 ) Share Today Pozen announced the submission of the new drug application to the U.S. FDA, seeking marketing approval for Vimovo for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk for developing NSAID-associated ulcers.

AstraZeneca said Tuesday that its development partner, Pozen Inc. has submitted a New Drug Application to the U.S. Food and Drug Administration for Vimovo tablets.

A veterinary professor at Kansas State University is considering new medication and food alternatives to the current methods of treating osteoarthritis in dogs.

StocksHaven Investments news portal takes a closer look at Nuvo Research Inc. , which hopes its novel osteoarthritis treatment Pennsaid will be approved by the FDA on August/5/09. Nuvo Research Inc.

Nuvo Research Inc. Nuvo Research Inc. has been red hot this past month and is expected to continue.

Stem Cell Therapy Effective for Tendonitis in Cornell Study According to Dr. Alan J. Nixon of Cornell University, veterinarians might be able to treat horses with injuries to their superficial digital flexor tendons effectively by injecting stem cells directly into the injured tendon using cells that were harvested and expanded from the horse's own ...

Jun 12, 2009 - CombinatoRx, Incorporated today announced the presentation of full data on Synavive Phase 2 knee osteoarthritis trial at EULAR 2009, the Annual European Congress of Rheumatology in Copenhagen on June 12, 2009.

Sophia Antipolis, France, June 12, 2009 -- NicOx S.A. today announced that several scientific posters on naproxcinod results were presented yesterday at the European League Against Rheumatism Congress in Copenhagen, Denmark.

Researchers in Israel have proposed using injections of fat globules using nanotechnology to relieve the symptoms of osteoarthritis .

The Institute of Food Technologists asserted new natural treatments may help improve the quality of life for more than 21 million osteoarthritis sufferers, according to new research presented at their annual meeting.

June 9, 2009. Sophia Antipolis, France-NicOx S.A. today announced the full scientific publication of results from the ZEST phase 2 study for naproxcinod in the June issue of the Journal of Rheumatology1, an international peer-reviewed scientific journal.

Anika Therapeutics, Inc. today announced that it has signed an exclusive U.S. distribution agreement with Palo Alto, California-based Coapt Systems, Inc.

New natural treatments may help improve the quality of life for more than 21 million osteoarthritis sufferers, according to new research presented at the 2009 Institute of Food Technologists Annual Meeting and Food Expo.

CombinatoRx Inc. reported positive Phase 1 clinical study results of Synavive, its knee treatment for osteoarthritis.

Anika Therapeutics, Inc. today announced the appointment of Frank J. Luppino as chief operating officer.

The prospects for the treatment of arthritis are bright as many new and safer medicines have been developed for pain management, says Weill Cornell Medical College's associate professor Dr Thurayya Arayssi.

Links not loading properly? Some of our pages use Portable Document Format files, which require Adobe Acrobat Reader.